Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma
The CPR model suggests that cilta-cel offers substantial clinical and economic benefit for patients with RRMM compared with RW-SoC therapies.
Authors
- Eileen Zhang
- Sundar Jagannath
- Seina Lee
- Matthew Perciavalle (ORCID: https://orcid.org/0000-0003-4572-9906)
- Xiaoxiao Lu (ORCID: https://orcid.org/0000-0001-6855-9298)
- Stephen Huo
- Denise De Wiest
- Omar Castaneda Puglianini
- Rameet Sachdev
- Saad Z Usmani
- Doris K Hansen
- Zaina P Qureshi
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Janssen (Belgium) (BE)
- Moffitt Cancer Center (US)
- 490 BioTech (United States) (US)
- Janssen (Switzerland) (CH)
- Global Services (Slovakia) (SK)
- Thermo Fisher Scientific (United States) (US)
- Janssen Scientific Affairs (United States)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1080/14737167.2026.2634771
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00